Skip to main content
Premium Trial:

Request an Annual Quote

Dharmacon to Provide siRNAs to Bayer

NEW YORK, Nov. 10 (GenomeWeb News) - Dharmacon said today that it has signed an agreement to provide custom siRNA reagents to Bayer for use in target validation and drug development projects.

 

Financial terms of the arrangment were not disclosed.

 

Dharmacon has recently struck a number of similar deals with other drugmakers, including Abbott, Exelixis, and Odyssey Thera.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.